Healthcare professionals should monitor ALT, AST, and bilirubin levels closely before each dose (or more frequently if clinically indicated); and continue monitoring for up to 6 months after the last dose. Patients should be advised to seek urgent medical attention if they develop any symptoms or signs of potential hepatic injury.